Drug news
Puma Biotechnology licenses neratinib for Breast Cancer from Pfizer
Pfizer has granted a worldwide licence of neratinib, its Phase-III oral tyrosine kinase inhibitor, to Puma Biotechnology. Neratinib is a novel treatment of Breast Cancer being an inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.